As in many other developing countries of the world, mental health research in Ghana has received little attention. The epidemiology of the disease and the actual prevalence in the general population are virtually unknown. Few small scale studies have identified factors associated with depression in the country. Nonetheless, because of their limited scope, quality and scale of these studies, there remains a gap in knowledge regarding factors associated with depression in a general population. Therefore, the purpose of the study is to examine the prevalence of self-reported depression among adults (age > 18) and analyze the association between demographic, socio-economic, health conditions, and life-style practices and presence of depression in a West African country (Ghana) using 2002 World Health Survey. METHODS: Cross-sectional design was used. Data were extracted from the World Health Survey for the year 2002. Based on an algorithm developed by Ayuso-Mateos and colleagues using World Health Survey, we combined depressive episode, brief episode and subsyndromal depression to measure presence of depression. Chi square statistics and logistic regressions were utilized to examine the relationship between self-reported depression and demographic, socio-economic, health conditions, and life-style practices in Ghana. RESULTS: Overall, 11.9% adults reported depression. Logistic regression on presence of depression revealed that women were more likely to have depression compared to men (AOR = 1.46, 95% CI = 1.13, 1.89). Among other factors, those with chronic conditions (arthritis and heart disease) were more likely to have depression compared to those without these conditions. CONCLUSIONS: This study confirms the gender differences in prevalence of depression. The relationship between chronic conditions and depression highlights the need for medical and behavioral treatment integration in Ghana.
Objective: To predict the demographic, diagnostic, comorbid, and drug utilization factors that may impact the likelihood of subjects initiating lurasidone among US employers. Methods: Analyses of administrative claims data from the HCMS Database comprised of multiple large geographically dispersed US employers from 2/1/2011(lurasidone launch) through 9/30/2012. All continuously enrolled subjects with a schizophrenia or bipolar disorder diagnosis with a prescription claim of lurasidone were classified as lurasidone subjects; those without a lurasidone prescription claim were controls. Demographics, Charlson comorbidity index (CCI) score, specific bipolar disorder or schizophrenia diagnoses, and use of atypical antipsychotics were described using means for continuous variables and proportions for categorical variables. Factors predicting the likelihood of initiating lurasidone were evaluated using stepwise logistic regression. Results: From a total of 127 lurasidone subjects and 7754 controls, 43 lurasidone subjects (1.1%) and 3822 control subjects were eligible for analysis with 40.4% employees, 31.2% spouses, and 28.4% dependents. The employees/spouses were 67% female, mean age 44.1 (SD=10.8) years and mean CCI score of 0.72 (SD=1.42). Dependents were 49% female, with mean age 20.7 (SD=7.4) years and mean CCI score of 0.27 (SD=0.72). The most commonly used atypical antipsychotics were: aripiprazole=18.6%, quetiapine=18.3%, risperidone=11.6%, olanzapine=6.2%, and ziprasidone=5.7%. Logistic regression found subjects with schizoaffective disorder (ICD-9=295.7x, OR=3.6, P=0.0023); use of paliperidone (OR=7.8, P<0.0001), ziprasidone (OR=5.3, P<0.0001), or aripiprazole (OR=2.1, P=0.0233); and younger ages (OR=0.97, P=0.0244) were more likely to initiate lurasidone. Conclusion: This analysis suggests that subjects with schizoaffective disorder and paliperidone, ziprasidone, aripiprazole use were >2 times as likely to take lurasidone compared to controls. Additionally, younger subjects were more likely to take lurasidone.
PMH19 MENTAL COMORBIDITY AND IN-HOSPITAL MORTALITY AMONG PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Sohn M, Moga DC, Talbert J University of Kentucky, Lexington, KY, USA OBJECTIVES: This study examines whether mental comorbidity affects inhospital mortality among individuals with acute myocardial infarction (AMI). The present study uses nationally representative data and provides insight for understanding the impact of mental comorbidity on in-hospital outcomes among individuals with AMI. METHODS: The Nationwide Inpatient Sample (NIS) database of the Health Care Cost and Utilization Project (HCUP) for 2010 was used to identify cases where the primary diagnoses at discharge was AMI (ICD-9-CM; 410.XX). Mental comorbidity cases were identified as discharges with 1 or more mental disorders (ICD-9-CM; 290.XX-319.XX) listed as the non-primary diagnosis. The impact of mental comorbidities on in-hospital mortality was evaluated using Cox proportional hazards regression. RESULTS: A total of 232,813 cases with AMI were included in the analysis. Of these, 112,327 (48%) had at least one diagnosis of a mental comorbidity. According to the Cox proportional hazards estimation result, the presence of mental comorbidity significantly increases the probability of having in-hospital death (Hazard Ratio: 1.34, 95% CI: 1.23-1.46). CONCLUSIONS: Our results suggest that mental conditions could increase in-hospital mortality among individuals with AMI. Whether having mental comorbidities is per se a risk factor for in-hospital mortality post-AMI or is a proxy for other unmeasured factors needs further investigation. Regardless, our finding suggests that presence of mental comorbidities should be accounted for when treating patients. Depression and/or anxiety and normal BMI; 5) Depression and/or anxiety and overweight; 6) Depression and/or anxiety and obese. Binary outcome variables indicating presence/absence of asthma, arthritis, diabetes, gastro esophageal reflux disease (GERD), chronic obstructive pulmonary disorder, hypertension, heart disease, osteoporosis, and thyroid disorders, were outcome measures. Exponentiated coefficients from two separate complementary log-log regressions were used to determine the risk of chronic physical conditions in presence obesity and depression and/anxiety. We tested the independent association of depression and/or anxiety with risk of chronic physical conditions by specifying two contrasts using the following reference groups 'no depression and no anxiety with obesity' and 'no depression and no anxiety and normal BMI' in two separate regression models. RESULTS: Among individuals with obesity, those with depression and/or anxiety were at higher risk of having chronic physical conditions (except osteoporosis) compared to individuals with no depression and no anxiety. The Adjusted Risk Ratios (ARRs) ranged from 2.07 (95% CI: 1.73, 2.48) for GERD to 1.29 (95%CI: 1.07, 1.56) for asthma. Among individuals with normal BMI, those with depression and/or anxiety were at higher risk of having chronic physical conditions compared to individuals with no depression and no anxiety. The ARRs ranged from 2.30 (95%CI: 1.69, 3.13) for GERD to 1.44 (95%CI: 1.22, 1.69) for arthritis. CONCLUSIONS: Presence of depression and/or anxiety conferred an independent risk for having chronic physical conditions after regardless of BMI categories. Kulikov A, Komarov I I.M. Sechenov First Moscow State Medical University, Moscow, Russia OBJECTIVES: To estimate the budget impact of the inclusion of quetiapine compared to aripiprazole or olanzapine on the top of standard bipolar disorder treatment scheme with atypical antipsychotics according to Russian health care system. METHODS: The one year budget impact analysis was conducted. Direct expenses associated with bipolar disorder and resulting follow-up costs were calculated using general tariff agreement of Russian obligatory insurance system and official national statistics. For reference, accepted exchange rate was 1 EUR = 40 RUB. RESULTS: Quetiapine inclusion into the standard bipolar disorder therapy provided cost saving benefits compared with inclusion of aripiprazole or olanzapine in the bipolar disorder standard therapy scheme. Total health care costs of bipolar disorder therapy were approximately 396 539 RUB (9,913 EUR) per patient in quetiapine group, 1,023 089 RUB (25,577 EUR) per patient in aripiprazole group and 557,222 RUB (13,931 EUR) per patient in olanzapine group within one year. Treatment of bipolar disorder using standard therapy with quetiapine inclusion compared to one with aripiprazole or olanzapine leads to cost savings of 626,551 RUB (15,664 EUR) or 160,683 RUB (4,017 EUR) per patientyear, respectively. CONCLUSIONS: The results of budget impact analysis illustrate that including quetiapine into the standard therapy of bipolar disorder in comparison with aripiprazole or olanzapine has potential to reduce Russian health care system total costs for bipolar disorder treatment.
MENTAL HEALTH -Cost Studies

PMH21 BUDGET IMPACT ANALYSIS OF QUETIAPINE VERSUS ARIPIPRAZOLE OR OLANZAPINE ON THE TOP OF STANDARD THERAPY IN THE TREATMENT OF BIPOLAR DISORDER IN RUSSIAN FEDERATION
PMH22
ANALYSIS OF PERSISTENCE AND HEALTH CARE COSTS IN THE US MEDICAID POPULATION OPIOID-DEPENDENT PATIENTS TREATED WITH BUPRENORPHINE/NALOXONE FILM AND TABLET FORMULATIONS
